EDIT Overview
Upcoming Projects (EDIT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (EDIT)
-
Digging into Editas' EdiThal Trial for Renizgamglogene Autogedtemcel in Transfusion-Dependent Beta-Thalassemia
Ticker: EDIT
Executed On: Jul 31, 2024 at 09:30 AM EDT -
Reviewing EDIT-301 as an experimental cell therapy medicine for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: EDIT, VRTX, BLUE, CRSP
Executed On: Mar 03, 2023 at 10:00 AM EST -
Discussing the IPSC and NK cell infusion landscape in the oncology space with a focus on technologies in development by Editas and Fate Therapeutics
Tickers: FATE, EDIT
Executed On: Jan 19, 2022 at 02:00 PM EST
Expired Projects (EDIT)
Upcoming & Overdue Catalysts (EDIT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (EDIT)
-
Editas Medicine (EDIT) plans to submit IND application for LCA10, a vaccine for eye disease,in the middle of 2018
Ticker: EDIT
Occurred on: Nov 30, 2018 -
Editas Medicine (EDIT) to initiate natural history trial LCA10, a vaccine for eye disease, in the middle of 2017
Ticker: EDIT
Occurred on: Aug 09, 2017
Strategic Initiatives (EDIT)
-
Allergan (AGN) Announces Exclusive R&D Partnership with Editas (EDIT) for Five Gene-Editing Ocular Programs
Tickers: AGN, EDIT
Announcement Date: Mar 14, 2017
